HIT-REZ-REGISTER - a multinational multicentre register for children, adolescents, and young adults with refractory, progressive or relapsed medulloblastomas, pineoblastomas, primitive neuroectodermal tumors of the CNS (CNS-PNETs) and ependymomas - HIT-REZ-Register

niversitätsklinikum Essen0 个研究点目标入组 278 人开始时间: 2015年7月14日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Medulloblastoma, pineoblastoma or other tumors of the pineal region (pineocytoma and germ cell tumors are exluded), CNS-PNETs (CNS neuroblastoma, CNS ganglioneuroblastoma,
•medulloepithelioma, ependymoblastoma) or ependymoma (WHO-Grade II or III) independently of the localization of the primary tumor (supratentorial, infratentorial, spinal); reference neuropathologically proven histology at new diagnosis and at relapse in case of re-operation; reference radiologically (MRI cranial and holospinal) proven refractory or progressive disease during first-line treatment or at the first or a multiple relapse and/or histologically/cytologically proven relapse within a tissue sample or a CSF sample; relapse/progress diagnosis after 01/02/2013; Age = 3 months, no upper age limit; written informed consent by the patient/the parents/the guardians for data collection and analysis

•Enrollment into the HIT-REZ-97-Study or HIT-REZ-2005-Study
•Cave: The enrollment into a prospective clinical trial for relapses does not exclude the enrollment into the HIT-REZ-Registry. Refractory, progressive or relapsed diseases prior and after these prospective clinical trials can be analyzed within this registry.

发起方

niversitätsklinikum Essen